



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 31 May 2023

In compliance with the disclosure duties set out in article 227 of the consolidated text of Law 6/2023 of 17 March on Securities Markets and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter "**ROVI**" or the "**Company**") informs the National Securities Market Commission as follows:

OTHER RELEVANT INFORMATION

In relation to the news items that have appeared in several media today regarding ROVI's receipt of government grants, the Company wishes to state the following:

1. The Company is not a party in any legal proceedings concerning government grants and has not received any notification in this respect.
2. All the grants to which the Company and the companies belonging to its group have had access during their extensive business history have been lawful and were obtained in strict compliance with the legal requirements, including those concerning transparency, publicity and competition. ROVI has met the conditions established for said grants in full and has invested them in the corresponding projects. Furthermore, it is important to highlight the fact that the projects for which grants have been awarded have also been backed by significant private investments on the part of the Company, which have allowed them to materialise.
3. The Company does not know the source of the figures mentioned in the news items published and, at all events, categorically denies that it received public grants for sums of this magnitude in 2009 or any other period.

The Company confirms its firm commitment to investment in Spain, where all its production plants, which have positioned ROVI as a leading strategic company in the international pharmaceutical industry, are located.

Mr Juan López-Belmonte Encina

Chairman of the Board of Directors and Chief Executive Officer
Laboratorios Farmacéuticos Rovi, S.A.